Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

Live updates

1. 1h ago

   Merck and Moderna's cancer vaccine shows promise in preventing melanoma recurrence

   Merck and Moderna's personalized mRNA cancer vaccine, combined with pembrolizumab, has shown significant promise in preventing the recurrence of melanoma in high-risk patients. The vaccine, which targets individual tumors, successfully cleared phase 3 clinical trials. This treatment approach marks a shift towards personalized oncology, tailored to a patient's specific genetic makeup. The results suggest a potential new treatment option for patients at high risk of melanoma recurrence.

   Why it matters

   Melanoma is a serious form of skin cancer that can be life-threatening if not treated promptly. Current treatments often have varying degrees of success, and there is a need for more effective and targeted therapies. The development of personalized cancer vaccines represents a significant advancement in oncology, offering the potential for more effective and less toxic treatments. This approach has been made possible by advances in genetic sequencing and mRNA technology.

   What is confirmed

   • The personalized mRNA vaccine, combined with pembrolizumab, significantly reduces melanoma recurrence.
   • The treatment targets individual tumors to prevent skin cancer from returning in patients.
   • The vaccine successfully cleared phase 3 clinical trials.

   What to watch next

   • FDA approval of the vaccine
   • Results of further trials to confirm the vaccine's efficacy and safety
   • Potential approval and recommendation for use by regulatory bodies
   Sources used for this update (5)

   1. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
   2. www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
   3. www.sciencenews.org — A new cancer vaccine may keep melanoma from coming back
   4. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
   5. www.nbcnews.com — Two deaths reported in Pennsylvania measles outbreak
   confidence 100%
2. 3d ago

   Moderna and Merck mRNA vaccine clears phase 3 trial for melanoma recurrence

   Moderna and Merck developed a personalized mRNA cancer vaccine that significantly reduces melanoma recurrence when combined with the immunotherapy drug pembrolizumab. The treatment successfully cleared phase 3 clinical trials, which is the final step required before seeking FDA approval. This neoantigen treatment targets individual tumors to prevent skin cancer from returning in patients. The results suggest a shift toward personalized oncology treatments tailored to the specific genetic makeup of a patient's tumor.

   Why it matters

   Traditional cancer treatments often apply a one-size-fits-all approach. This vaccine uses mRNA technology to create a custom response based on a patient's specific tumor. Success in phase 3 trials indicates the treatment is ready for regulatory review.

   What is confirmed

   • Moderna and Merck developed a personalized mRNA vaccine to prevent melanoma recurrence.
   • The vaccine was used in combination with the immunotherapy drug pembrolizumab.
   • The treatment significantly reduced the risk of melanoma recurrence in a phase 3 trial.
   • The vaccine successfully cleared phase 3 clinical trials.

   What to watch next

   • FDA approval decision for the mRNA vaccine
   • Results from wider patient demographics or different cancer types
   Sources used for this update (4)

   1. baynews9.com — New study shows personalized vaccine may help prevent skin cancer from recurring in patients
   2. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
   3. www.smithsonianmag.com — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
   4. www.medicalnewstoday.com — Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
   confidence 100%
3. 5d ago

   Moderna, Merck cancer vaccine shows promise in melanoma trial

   Moderna and Merck's cancer vaccine has shown promise in preventing the recurrence of melanoma in a late-stage trial. The vaccine, which uses mRNA technology, has been found to be effective in reducing the risk of melanoma recurrence. The trial results have led to a surge in Moderna's stock price.

   Why it matters

   Melanoma is a type of skin cancer that can be deadly if not treated early. Current treatments for melanoma include surgery, chemotherapy, and immunotherapy. The development of a cancer vaccine could provide a new treatment option for patients with melanoma. The vaccine works by using mRNA to instruct the body's immune system to recognize and attack cancer cells.

   What is confirmed

   • Moderna and Merck's cancer vaccine shows promise in preventing recurrence of melanoma
   • The vaccine uses mRNA technology to instruct the body's immune system to recognize and attack cancer cells
   • Moderna's stock price has surged 90% following the release of positive trial results

   What to watch next

   • Future trial results and potential FDA approval
   • Details on the vaccine's safety and efficacy
   • Pricing and availability of the vaccine if approved
   Sources used for this update (11)

   1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
   2. NBC News — Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
   3. Bloomberg.com — Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss
   4. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
   5. cnn.com — Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
   6. Clinical Trials Arena — MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score
   7. People.com — New Melanoma Vaccine in Development Might Prevent Recurrence, Spread of Deadly Skin Cancer
   8. Yahoo Finance — Moderna stock surges as melanoma vaccine trial shows "landmark moment"
   9. Reuters — Moderna, Merck breakthrough could usher in wave of cancer vaccines
   10. WSJ — Opinion | Moderna’s Road to a Cancer Vaccine
   11. Reuters — Moderna shares double as cancer vaccine data rekindles investor hopes
   confidence 95%